Bayer's Final Word Before the Quiet

Bayer enters quiet period after CEO's final strategic address. Market focuses on Crop Science outlook, unchanged dividend, and pivotal US Supreme Court Roundup hearing.

The coming days represent a critical communications window for Bayer, bookended by a final strategic address and the onset of a corporate blackout period. On Monday evening, CEO Bill Anderson and Supervisory Board Chairman Norbert Winkeljohann will publish their speeches ahead of the Annual Stockholders' Meeting, offering investors a last glimpse of management's thinking before the company enters its official "Quiet Period."

From Monday until May 12, Bayer will refrain from analyst calls or commentary on business figures. This makes the published remarks a pivotal gauge for shareholder sentiment. The market's focus will be laser-sharp on the Crop Science division, which is navigating a declared transition year in 2025. Analysts expect concrete signals that the promised recovery in profitability for 2026 remains on track, moving beyond vague transformation rhetoric.

Financially, the company maintains a conservative stance. The board has proposed an unchanged dividend of 0.11 euros per share, identical to last year's payout, underscoring that debt reduction takes precedence over shareholder returns. The ex-dividend date is set for Monday, April 27.

The stock's technical picture reflects a market in wait-and-see mode. Shares closed Friday at 41.10 euros, trading precisely on the 50-day moving average—a neutral signal. Immediate resistance is seen around 42 euros, with psychological support just below at the 40-euro mark. This tight range is likely to contain trading action through the virtual Annual Meeting on Friday, April 24.

Beyond the immediate financial calendar, a monumental legal milestone looms. Just three days after the dividend date, on April 27, the US Supreme Court will hear arguments related to the weedkiller Roundup. This hearing is viewed as a potential turning point in the long-running litigation saga, with a favorable outcome capable of materially reducing the company's legal overhang.

The equity's performance underscores the high stakes. Having rallied approximately 95% from its April 2025 yearly low, the stock now trades well above its 200-day moving average of 34.09 euros. The Relative Strength Index (RSI) around 50 indicates neither overbought nor oversold conditions. Analyst sentiment has turned notably more constructive recently, with Deutsche Bank dramatically raising its price target from 23 to 43 euros, citing strength in agriculture offsetting pharmaceutical challenges. UBS maintains an even more optimistic view with a 52-euro target.

With the Quiet Period in effect, investors seeking fresh operational data must wait until Bayer's quarterly statement on May 12. Until then, the market will parse the published speeches and watch Washington, knowing that the outcomes could either challenge the key 40-euro support or bring the yearly high near 49 euros back into view.